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ment of patients with heart failure for risk stratiﬁcation and for im-
plementing treatment strategies.
OBJECTIVE The purpose of this study was to evaluate in patients
with implantable cardioverter-deﬁbrillators (ICDs) the performance
of the respiratory disturbance index (RDI) computed by the ApneaS-
can algorithm (Boston Scientiﬁc Inc., Natick, MA) as a discriminator
of severe SA.
METHODS ICD-indicated patients with left ventricular ejection
fraction 35% were enrolled. One month after implantation, pa-
tients underwent a polysomnographic study. We evaluated the accu-
racy of the RDI for the prediction of severe SA (apnea-hypopnea
index [AHI] 30 episodes/h) and the agreement between RDI
and AHI during the sleep study night.
RESULTS Two hundred sixty-ﬁve patients were enrolled to obtain
the required sample of 173 patients with AHI and RDI data for anal-
ysis. The mean AHI was 216 15 episodes/h and severe SA was diag-
nosed in 38 patients (22%), while the mean RDI was 33 6 13The DASAP-HF study is an independent study promoted by the Italian
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licenses/by-nc-nd/4.0/).episodes/h. On the basis of the receiver operating characteristic
curve analysis of RDI values, the area under the curve was 0.77
(95% conﬁdence interval [CI] 0.70–0.83; P, .001). At an RDI value
of 31 episodes/h, severe SA was detected with 87% (95% CI 72%–
96%) sensitivity and 56% (95% CI 48%–66%) speciﬁcity. RDI
closely correlated with AHI recorded during the same night
(r 5 0.74; 95% CI 0.57–0.84; P , .001), and the Bland-Altman
agreement analysis revealed a bias of 11 episodes/h, with limits
of agreement being 210 to 32 episodes/h.
CONCLUSION The RDI accurately identiﬁed severe SA and demon-
strated good agreement with AHI. Therefore, it may serve as an efﬁ-
cient tool for screening patients at risk of SA.
KEYWORDS Heart failure; ICD; Respiratory disturbances; Sleep
apnea; Thoracic impedance
(Heart Rhythm 2018;15:211–217) © 2017 The Authors. Published
by Elsevier Inc. on behalf of Heart Rhythm Society. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Sleep-disordered breathing is the most common comorbidity
in heart failure (HF), occurring in 30%–80% of the affected
patients.1,2 Obstructive sleep apnea (SA) is more common
and occurs both in the general population and in the
population with HF, whereas central SA is closely
ythm Society.
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212 Heart Rhythm, Vol 15, No 2, February 2018associated with HF.3 SA has been associated with the devel-
opment of hypertension4 and arrhythmias5–7 and has been
shown to have a negative prognostic value in HF.8 In partic-
ular, SA is an independent risk factor for malignant ventric-
ular arrhythmias, which require appropriate implantable
cardioverter-deﬁbrillator (ICD) therapies in patients with
HF.9
Although polysomnography is the diagnostic gold stan-
dard, access to this procedure is limited and frequently clin-
ically signiﬁcant SA remains undiagnosed.10 Alternative
methods of monitoring sleep-related breathing disorders are
therefore needed in patients with cardiovascular diseases at
higher risk of SA. Recently, automated algorithms based
on the continuous measurement of thoracic impedance
have been developed to detect advanced sleep-disordered
breathing.11 Somemodern pacemakers and ICD are equipped
with these algorithms and provide indices for the continuous
quantiﬁcation of the severity of SA.
The Diagnosis of Sleep Apnea in Patient With Heart Fail-
ure (DASAP-HF) study aimed at evaluating in patients with
an ICD the performance of the respiratory disturbance index
(RDI) computed by the ApneaScan algorithm (Boston Scien-
tiﬁc Inc., Natick, MA) as a discriminator of severe SA.Methods
Patient selection
The study was a prospective, nonrandomized, multicenter
evaluation of patients implanted with an ICD or cardiac
resynchronization therapy with ICD (CRT-D) endowed
with the ApneaScan diagnostic feature (the list of centers is
reported in Appendix 1). Patients had to present with current
ICD or CRT-D indications12,13 and with left ventricular
systolic dysfunction, that is, left ventricular ejection
fraction 35%. Patients already receiving CRT, those
unavailable to attend scheduled follow-up visits at the center,
or those with a life expectancy of ,12 months were all
excluded. The ethics committees approved the study, and
all patients gave written informed consent.
Study design
Devices and pacing leads were implanted by means of stan-
dard techniques. Baseline evaluation included demographic
characteristics and medical history, clinical examination,
12-lead electrocardiogram, and echocardiographic evalua-
tion. At 1 month after enrollment, patients underwent an
in-clinic visit. If RDI values were measured and stored by
the device within 7 days before the visit, a sleep study was
scheduled within 7 days. Otherwise, a new visit was planned
after 2 months (3 months from the enrollment). After the
sleep study, the implanted device was interrogated and stored
data were retrieved.
Sleep study recording
Each patient underwent an unattended home nocturnal
recording by means of a portable SA monitor (Embletta,
Broomﬁeld, CO) equipped with multiple sensors, inagreement with the current American Academy of Sleep
Medicine guidelines for the detection of respiratory events.14
The parameters recorded were oronasal airﬂow and air
temperature, thoracoabdominal movements through pleth-
ysmography, O2 saturation by a ﬁnger pulse oximeter,
body position and movement, and snoring. Recordings
were evaluated by a core laboratory, blinded to the values
recorded by the implanted device. Apnea was deﬁned as a
drop in the peak thermal sensor excursion by .90% of the
baseline value and lasting 10 seconds, and hypopnea
was deﬁned as a.50% reduction in oronasal airﬂow lasting
10 seconds together with a .3% drop in oxygen satura-
tion. The apnea-hypopnea index (AHI) was computed as
the number of apneas and hypopneas divided by the sleep
time analyzed, minus movement time and standing position
time. For the purposes of the present study, SA was deﬁned
as severe if the AHI was 30 episodes/h during the sleep
study night.11,15Device characteristics
Commercially available ICD/CRT-Ds and transvenous leads
were used in this study. Devices were equipped with the Ap-
neaScan diagnostic feature, which continuously measures
thoracic impedance by sending a low-voltage signal from
the lead and the ICD can. As thoracic impedance varies
with respiratory movements, changes in impedance are
used to create a waveform that is used to count respiration.
At the time of device programming, the diagnostic feature
is enabled and a programmable time period when the patient
is expected to be sleeping is set. At night, the algorithm auto-
matically detects apnea-hypopnea events by assessing the
amount of time between breaths that exceed aminimum base-
line value. The baseline is a weighted average of tidal vol-
umes, which is continually updated to account for small
changes. In case of sudden large increases or decreases in
the respiratory sensor signal after postural changes, the algo-
rithm quickly readjusts the baseline. After veriﬁcation of the
signal quality and validation of the respiratory interval mea-
surement, the algorithm deﬁnes an apnea episode as 2
consecutive large breaths, where the time between breaths
is .10 seconds, and a hypopnea episode as an interval be-
tween large breaths .10 seconds, which additionally con-
tains consecutive small breaths. The total number of apnea
and hypopnea events is stored, and the RDI is calculated
by dividing the number of events by the programmed sleep
duration. Data collection begins 1 hour after the programmed
start time and ends 1 hour before the end of the sleep
duration, so that data are not collected while the patient
is expected to fall asleep and wake-up. Moreover,
measurements are suspended during other ICD activities
(eg, capacitor charge, shock, and lead impedance measure-
ments). At least 2 hours of valid data must be obtained to
calculate the RDI value of the day. The RDI is presented as
a daily trend on device interrogation. The development of
the ApneaScan algorithm is based on data from a published
study.11
D’Onofrio et al Sleep Apnea Detection With Implanted Cardiac Devices 213SA prediction and analysis
The primary objective of this study was to evaluate the per-
formance of the device-calculated RDI value as a binary
discriminator of severe SA. For the analysis, the average
RDI value calculated by the algorithm over a 1-week period
preceding the sleep study was used.
The secondary objective was to assess the performance of
the RDI as a diagnostic tool by evaluating the agreement be-
tween RDI and AHI values. The RDI value recorded during
the same diagnosis night was then compared with the AHI.Figure 1 Patient disposition.
Table 1 Demographic characteristics and baseline clinical
parameters (N 5 173)
Parameter Value
Age (y) 68 6 10
Sex: male 139 (80)
Body mass index (kg/m2) 27 6 8
Primary prevention 152 (88)
NYHA class III–IV 91 (53)
QRS duration (ms) 126 6 38
Sinus rhythm 133 (77)
Ischemic heart disease 91 (53)
Hypertension 38 (22)
History of atrial ﬁbrillation 31 (18)
Pulmonary diseases 60 (35)
COPD 22 (13)
Chronic kidney disease 17 (10)
Diabetes 47 (27)
LV ejection fraction (%) 29 6 5
LVESV (mL) 84 6 74
LVEDV (mL) 122 6 99
Creatinine level (mg/dL) 1.08 6 0.62
ACE-inhibitor use 151 (87)Statistical analysis
Continuous data were expressed as mean 6 SD. Categorical
data were expressed as number (percentage). For the primary
objective, a receiver operating characteristic (ROC) curve
analysis was conducted to assess the performance of the
RDI as a predictor for SA (determined by the sleep study
on the basis of an AHI cutoff of 30 episodes/h). In our anal-
ysis, we optimized sensitivity and speciﬁcity simultaneously;
that is, we regarded the value resulting in the maximum prod-
uct of sensitivity and speciﬁcity on the curve as the optimal
cutoff. The sensitivity and speciﬁcity of the RDI were also
speciﬁed, along with 95% conﬁdence interval (CI), for an
RDI cutoff of 32 episodes/h (nominal cutoff for severe SA
in the ApneaScan algorithm).
The sample size for the analysis (170 patients) was esti-
mated on the basis of the assumption that the study would
have 90% power to detect a difference from the area under
the curve (AUC) of 0.5 (equivalently RDI had no predictive
value), with 0.68 expected AUC and 20% prevalence of SA.
Considering 30% of unavailable RDI values and 15% of
sleep studies not adequately performed or not scheduled on
time, a maximum sample of 320 subjects was considered to
allow the analysis of the primary objective. Nonetheless,
the enrollment was interrupted as soon as the target of 170 pa-
tients in the analysis was achieved.
The performance of the RDI as a diagnostic tool was deter-
mined by comparing all available RDI and AHI values re-
corded during the sleep study night. Agreement between
the 2 indices was computed as the bias (mean), with limits
of agreement computed as bias6 2SD when differences fol-
lowed normal distribution.16 Normality was tested by means
of the Kolmogorov-Smirnov 1-sample test. Statistical corre-
lations between variables were tested by means of linear
regression analysis. A P value of,.05 was considered signif-
icant for all tests. All statistical analyses were performed by
means of Statistica software, version 7.1 (StatSoft, Inc.,
Palo Alto, CA).Aldosterone antagonist use 100 (58)
b-Blocker use 165 (96)
Diuretic use 162 (94)
Antiarrhythmic drug use 44 (25)
CRT-D device 87 (50)
Values are presented as mean 6 SD or as n (%).
ACE 5 angiotensin-converting enzyme; CRT-D 5 cardiac resynchroniza-
tion therapy–deﬁbrillator; COPD 5 chronic obstructive pulmonary disease;
LV 5 left ventricular; LVEDV 5 left ventricular end-diastolic volume; LVESV
5 left ventricular end-systolic volume; NYHA5 New York Heart Association.Results
Study population
A total of 265 patients were enrolled in the study between
March 31, 2014 and July 6, 2016 at 13 centers in Italy and
Spain. Nine patients died before the visit at 1 or 3 months.
In 75 patients no RDI values were recorded by the ICDwithin
7 days before the visit, while 8 patients did not undergo thescheduled sleep study. The remaining 173 patients under-
went home nocturnal recording, and stored data were
retrieved from the implanted device (Figure 1). Table 1 lists
baseline clinical variables.Sleep study and SA detection
The mean AHI value on the polygraphic recording was 216
15 episodes/h, and severe SA was diagnosed in 38 patients
Figure 2 Receiver operating characteristic curve analysis of the RDI. Sensitivity and speciﬁcity were 87% (95% conﬁdence interval 72%–96%) and 56% (95%
conﬁdence interval 48%–66%), respectively, at 31 episodes/h. AHI 5 apnea-hypopnea index; RDI 5 respiratory disturbance index.
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Figure 3 Examples of respiratory disturbance index values in patients
with and without severe sleep apnea (AHI 5 56 episodes/h and AHI 5 10
episodes/h, respectively). The data collected before the sleep study visit
were available on device interrogation and presented as a daily trend. AHI
5 apnea-hypopnea index.
214 Heart Rhythm, Vol 15, No 2, February 2018(22%) (AHI 30 episodes/h). Among patients with severe
SA, 19 (50%) had a predominance of central apnea, 16
(42%) obstructive apnea, and 3 (8%) mixed apnea.
Primary end point
The mean RDI value recorded by the implanted devices dur-
ing the week preceding the study night was 336 13 episodes/
h. On the basis of the ROC curve analysis of RDI values for
the prediction of severe SA, the AUC was 0.77 (95% CI
0.70–0.83; P , .001) (Figure 2). The cutoff that best identi-
ﬁed severe SA and maximized sensibility and speciﬁcity was
31 episodes/h. It enabled severe SA to be detected with 87%
(95% CI 72%–96%) sensitivity and 56% (95% CI 48%–
66%) speciﬁcity. When a cutoff of 32 episodes/h (nominal
cutoff for severe SA in the ApneaScan algorithm) was adop-
ted, the sensitivity and speciﬁcity were 79% (95% CI 63%–
90%) and 58% (95% CI 50%–67%), respectively. Two
examples of RDI values in patients with and without severe
SA are presented in Figure 3.
The results of the ROC curve analysis of RDI values for
the prediction of severe SA in speciﬁc subgroups are pre-
sented in Table 2. The RDI was equally accurate in detecting
severe SA across subgroups.
Secondary end point
The performance of the RDI as a diagnostic tool was deter-
mined by comparing the RDI and AHI values during the
sleep study night. In 49 (28%) of the 173 patients in the anal-
ysis, the RDI and AHI values were available for the same
night. The mean AHI value was 20 6 15 episodes/h, and
the RDI was 31 6 14 episodes/h. The RDI value closely
correlated with the AHI value (r 5 0.74; 95% CI 0.57–
0.84; P , .001). The Bland-Altman agreement analysis be-
tween RDI and AHI values during the sleep study night re-
vealed a bias between measurements of 11 episodes/h, with
limits of agreement being 210 to 32 episodes/h. The regres-
sion line of differences showed an intercept coefﬁcient of
13.0 (95% CI 6.4–19.7; P , .001) and a slope coefﬁcientof 20.07 (95% CI 20.30 to 0.16; P 5 .561) (Figure 4).
The agreement analysis performed in patients with nonsevere
SA revealed a bias between measurements of 14 episodes/h,
with limits of agreement being 23 to 31 episodes/h. In this
subgroup, the correlation coefﬁcient between RDI and AHI
values was 0.64 (95% CI 0.41–0.79; P , .001). In patients
with severe SA, the bias between measurements was 21
episodes/h, with limits of agreement being 222 to 21 epi-
sodes/h. In this subgroup, the correlation coefﬁcient between
RDI and AHI values was 0.80 (95% CI 0.30–0.96; P5 .009)
(Figure 4).Discussion
The present study demonstrated that the device-computed
RDI was able to accurately predict severe SA in patients
who received an ICD/CRT-D endowed with the ApneaScan
algorithm.Moreover, good agreement was seen between RDI
Table 2 Results of the receiver operating characteristic curve analysis of RDI values for the prediction of severe sleep apnea in speciﬁc
subgroups
Variable Area under the curve 95% conﬁdence interval P
CRT-D recipient (n 5 87) 0.75 0.64–0.83 ,.001
No CRT-D recipient (n 5 86) 0.78 0.68–0.87 ,.001
Diagnosed pulmonary diseases (n 5 60) 0.80 0.61–0.92 ,.001
Undiagnosed pulmonary diseases (n 5 113) 0.74 0.64–0.81 ,.001
Predominant central apnea (n 5 61) 0.73 0.60–0.84 .001
Predominant obstructive apnea (n 5 72) 0.77 0.65–0.86 ,.001
CRT-D 5 cardiac resynchronization therapy–deﬁbrillator; RDI 5 respiratory disturbance index.
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means of a standard home nocturnal polygraphic recording.
Sleep-related breathing disorders are frequent in patients
with cardiovascular disease.17 Cardiac arrhythmias are
more frequent in persons with obstructive SA and increase
with the number of apneic episodes.18 Nocturnal arrhythmias
have been shown to occur in up to 50% of patients with
obstructive SA, the most common being nonsustained ven-
tricular tachycardia, sinus arrest, atrioventricular conduction
block, and frequent premature ventricular contractions.6,7
Moreover, obstructive SA has been shown to affect a
higher proportion of patients with a history of atrial
ﬁbrillation than of the general population.19
According to the recommendations from American20,21
and European22 guidelines, clinical judgment should be
used to screen for sleep-disordered breathing in patientsFigure 4 A: Diagram showing RDI and AHI values measured during the sleep s
between indices; average index is their mean. The solid line indicates the bias and th
differences is shown with its 95% conﬁdence interval. C: Bland-Altman plot for pa
patients with severe SA (AHI 30 episodes/h). AHI 5 apnea-hypopnea index; RDwith HF. However, although patients who are hospitalized
with an admission diagnosis of acute HF have a high likeli-
hood of testing positive for sleep-disordered breathing,23,24
sleep studies are rarely performed in hospitals as routine
clinical care. The reasons why few HF programs
investigate coexisting SA are that most patients with HF do
not complain of daytime sleepiness or other features of
SA25 and that the diagnosis of SA requires overnight poly-
somnography performed in a sleep laboratory. During the
test, multiple physiological variables are recorded continu-
ously. These variables generally include sleep staging by
means of an electroencephalogram, electromyogram,
electro-oculogram, respiration, and snoring. Through these
signals, disordered breathing and its effect on sleep and
oxygenation can be precisely quantiﬁed.14 Access to poly-
somnography is limited, as it requires special institutionstudy night in 49 patients. B: Bland-Altman plots. RDI-AHI is the difference
e dashed lines the limits of agreement between indices. The regression line of
tients with non-severe SA (AHI,30 episodes/h). D: Bland-Altman plot for
I 5 respiratory disturbance index.
216 Heart Rhythm, Vol 15, No 2, February 2018and trained technicians and is relatively expensive. This
problem of timely access results in undiagnosed and under-
treated SA, as well as excessively long waiting lists.26,27
Indeed, in clinical practice, .85% of patients with
clinically signiﬁcant and treatable obstructive SA are not
diagnosed by means of standard methods.28,29 This is
conﬁrmed by the high proportion of patients with a history
of undiagnosed severe SA (22%) in our series.
Alternative methods for screening patients for sleep-
disordered breathing have been proposed, though their sensi-
tivity and speciﬁcity have not always been assessed. Some of
these options include questionnaires, overnight oximetry,
and devices combining limited respiratory assessment.
Recently, some modern pacemakers and ICDs have been
equipped with automated algorithms for the automatic detec-
tion of advanced sleep-disordered breathing.11 In the present
study, we measured the performance of one such algorithm in
a population of patients with no prior diagnosis of sleep-
disordered breathing. We enrolled unselected patients with
systolic HF with current ICD/CRT-D indications, thus
ensuring the external validity of our results.
The average RDI value calculated by the ICD over a
1-week period accurately identiﬁed patients with severe
disordered breathing on the polygraphic recording subse-
quently performed. Therefore, the ICD diagnostics may serve
as an efﬁcient tool for screening patients at risk of SA.
Patients identiﬁed by the automatic algorithm may therefore
subsequently undergo standard polysomnography to conﬁrm
the diagnosis, determine the type of SA, and then guide the
treatment decision. In our analysis, the RDI was equally
accurate in detecting severe SA across prespeciﬁed sub-
groups. Indeed, the accuracy of the algorithm seemed high
regardless of CRT, previous diagnosis of pulmonary disor-
ders, or type of SA. The ApneaScan algorithm is currently
available in the European market, and the results of the
DASAP-HF study are completely in line with the intended
use statement, that is, providing data that, along with other
clinical information, could be used to identify and follow
changes in patients who may be at high risk of sleep-
disordered breathing. While for the actual diagnosis of SA,
the manufacturer suggests to rely only on standard clinical
methods such as polysomnography.
In the present study, we also demonstrated good agree-
ment between AHI and RDI values recorded during the sleep
study night, showing good performance of the algorithm as a
diagnostic tool. Nonetheless, we showed a systematic bias to-
ward overestimation of the RDI (11 episodes/h). In partic-
ular, the RDI performed well, with no bias between
measurements, in patients with frequent SA episodes. How-
ever in patients with less frequent SA episodes (AHI ,30
episodes/h), the RDI value was affected by a positive bias
and the correlation with the AHI was lower. This could be
ascribed to the sensitivity value adopted by the algorithm
to detect breathing events or to the gradual adjustments in
the reference tidal volume continuously performed by the
system to account for possible postural changes. Another
possible source of error could be an imprecise setting of thesleep time at ICD implantation. Indeed, the system collects
data during a ﬁxed time period when the patient is expected
to be sleeping. Further reﬁnements of the algorithm may
include integration of multiple sensors to automatically
assess sleep time.30 Although the automatic detection of res-
piratory disturbances by ICDs should not be intended as a
comprehensive alternative to a standard sleep study, this
last ﬁnding supports the possible use of the RDI as a tool
for the continuous monitoring of respiratory disturbances.
Recently, Mazza et al31 investigated the relationship be-
tween the ApneaScan-measured RDI and the occurrence of
atrial ﬁbrillation in patients who received a pacemaker en-
dowed with the algorithm. Their ﬁndings suggest an addi-
tional potential use of the diagnostics, as device-detected
severe SA was independently associated with a higher risk
of new-onset atrial ﬁbrillation. In particular, severe SA on
follow-up data review identiﬁed patients who were about
twice more likely to experience an atrial ﬁbrillation episode
in the next 3 months. The long-term follow-up of patients
enrolled in the DASAP-HF study will allow to conﬁrm this
preliminary result and extend it by testing the association be-
tween ICD-detected SA and the clinical outcome.
Study limitations
The present study lacked a test set for independent validation
of the algorithm performance, and therefore the RDI cutoff
value for severe SA identiﬁcation must be interpreted with
caution. Although the present study allowed to demonstrate
the ability of the RDI to screen patients at risk of severe
SA, it did not assess the clinical impact of its adoption. Spe-
ciﬁc screening protocols should be implemented and tested to
verify the effectiveness and efﬁciency of this novel tool in
clinical practice.Conclusion
The ICD-computed RDI accurately identiﬁed severe SA and
demonstrated good agreement with AHI values measured
during the same night by ambulatory polygraphy. The RDI
may serve as an efﬁcient tool for screening patients at risk
of severe SA. The ability of ICDs to continuously and
remotely monitor respiratory disturbances could allow both
the evolution of SA and the possible impact of therapeutic
interventions to be assessed.Acknowledgments
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